Ashermed

About Ashermed

Ashermed, established in 2013, operates as a contract research organization (CRO) with a strong focus on digital innovation. The Shanghai-based company has positioned itself at the intersection of traditional clinical research and modern technology, integrating big data and artificial intelligence to enhance its service offerings. This strategic approach is designed to accelerate drug development timelines, improve the quality of clinical data, and reduce overall research and development costs for its clients in the medical field.

The company's business model centers on providing a comprehensive, digitally-enabled platform for clinical research. Ashermed has built a patient-centric ecosystem that handles a wide array of services including subject screening, recruitment, financial assistance, education, and follow-up. By leveraging its proprietary digital platform, Ashermed effectively manages and integrates resources from clinical experts and industry associations. This allows the firm to offer precise medical value communication services grounded in evidence-based medicine. The company generates revenue by providing these specialized CRO services and platform access to pharmaceutical and medical device companies.

Ashermed's service portfolio demonstrates its capability to manage complex, large-scale studies. The company has successfully executed projects such as a long-term follow-up study for chronic hepatitis B, enrolling over 8,000 patients across more than 400 hospitals, and has developed an AI-powered platform for a hematology drug study. Another notable project involved a prospective real-world study for an anti-tumor drug, which resulted in findings presented at major international oncology conferences. Through a partnership with JD.com, Ashermed co-founded a management platform for rare disease patients, successfully gathering data from over 6,000 ALS patients within its first year. The firm has attracted significant investment, raising $23.4 million in a Series B funding round in April 2022 from investors including Qiming Venture Partners and DHLT Investment.